Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02605122

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia

Sponsor: Biomedical Advanced Research and Development Authority

Conditions Community-acquired Bacterial Pneumonia

Interventions Solithromycin Standard of Care

Updated 15 times since 2017 Last updated: Dec 12, 2018 Started: Apr 30, 2016 Primary completion: Mar 21, 2018 Completion: Mar 21, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Development not proceeding

Other terminated trials from Biomedical Advanced Research and Development Authority

See all terminations from Biomedical Advanced Research and Development Authority

This PHASE2/PHASE3 trial investigates Community-acquired Bacterial Pneumonia and is currently terminated or withdrawn. Biomedical Advanced Research and Development Authority leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

15 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2025 — Feb 2026 [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3

▶ Show 10 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2_PHASE3
May 2019 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Feb 2019 — May 2019 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Feb 2019 [monthly]

Terminated PHASE2_PHASE3

Status: Recruiting → Terminated
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE2_PHASE3
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE2_PHASE3
Apr 2017 — Jun 2017 [monthly]

Recruiting PHASE2_PHASE3
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Advanced Research and Development Authority
Melinta Therapeutics, Inc.

Data source: Melinta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Barcelona, Spain , Budapest, Hungary , Caloocan, Philippines , Cebu City, Philippines , Cegléd, Hungary , Charlottesville, United States , City of Muntinlupa, Philippines , Davao City, Philippines , Debrecen, Hungary and 40 more locations